Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald S Go

Showing results (91-100 of 402) with videos related to

Pageof 41
Sort By:
The American Journal of Managed Care|March 22, 2023
Neulasta Onpro: a coup de grâce?Chelsee J Jensen, Caleb J Scheckel, Ronald S Go, et al.
Leukemia Research|December 17, 2021
Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approvalJohn W Thomas, Omer Jamy, Mithun Vinod Shah, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 4, 2017
<sup>18</sup>F-FDG PET/CT in Erdheim-Chester Disease: Imaging Findings and Potential BRAF Mutation BiomarkerJason R Young, Geoffrey B Johnson, Robert C Murphy, et al.
American Journal of Clinical Oncology|February 13, 2014
Speed of Accrual Into Phase III Oncology Trials: A Comparison Across Geographic LocationsNancy R Ruther, Michelle A Mathiason, Sandra K Wee, et al.
American Journal of Clinical Oncology|February 6, 2009
Extent and nature of advertising in leading hematology-oncology journalsDebbie L Sieber, Jennifer A Lee, Michelle A Mathiason, et al.
Advances in Radiation Oncology|February 3, 2025
Hypofractionated Radiation Therapy for Subcutaneous Rosai-Dorfman Disease: A Case ReportRachael M Guenzel, William G Breen, Ronald S Go, et al.
The American Journal of Managed Care|May 25, 2023
Provider barriers in uptake of biosimilars: case study on filgrastimJessica Chang, Pinar Karaca-Mandic, Ronald S Go, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|September 19, 2018
Monoclonal Gammopathy of Undetermined Significance: Follow-up Patterns in the United States and Concordance With Clinical Practice GuidelinesRonald S Go, Herbert C Heien, Lindsey R Sangaralingham, et al.
Haematologica|December 23, 2017
Risk of progression of monoclonal gammopathy of undetermined significance into lymphoplasmacytic malignancies: determining demographic differences in the USARonald S Go, Herbert C Heien, Lindsey R Sangaralingham, et al.
The American Journal of Managed Care|August 30, 2021
Site of care potentially limits cost savings from biosimilarsJessica Chang, Pinar Karaca-Mandic, Ronald S Go, et al.
Pageof 41

Showing results (91-100 of 402) with videos related to

Sort By:
Pageof 41
The American Journal of Managed Care|March 22, 2023
Neulasta Onpro: a coup de grâce?Chelsee J Jensen, Caleb J Scheckel, Ronald S Go, et al.
Leukemia Research|December 17, 2021
Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approvalJohn W Thomas, Omer Jamy, Mithun Vinod Shah, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 4, 2017
<sup>18</sup>F-FDG PET/CT in Erdheim-Chester Disease: Imaging Findings and Potential BRAF Mutation BiomarkerJason R Young, Geoffrey B Johnson, Robert C Murphy, et al.
American Journal of Clinical Oncology|February 13, 2014
Speed of Accrual Into Phase III Oncology Trials: A Comparison Across Geographic LocationsNancy R Ruther, Michelle A Mathiason, Sandra K Wee, et al.
American Journal of Clinical Oncology|February 6, 2009
Extent and nature of advertising in leading hematology-oncology journalsDebbie L Sieber, Jennifer A Lee, Michelle A Mathiason, et al.
Advances in Radiation Oncology|February 3, 2025
Hypofractionated Radiation Therapy for Subcutaneous Rosai-Dorfman Disease: A Case ReportRachael M Guenzel, William G Breen, Ronald S Go, et al.
The American Journal of Managed Care|May 25, 2023
Provider barriers in uptake of biosimilars: case study on filgrastimJessica Chang, Pinar Karaca-Mandic, Ronald S Go, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|September 19, 2018
Monoclonal Gammopathy of Undetermined Significance: Follow-up Patterns in the United States and Concordance With Clinical Practice GuidelinesRonald S Go, Herbert C Heien, Lindsey R Sangaralingham, et al.
Haematologica|December 23, 2017
Risk of progression of monoclonal gammopathy of undetermined significance into lymphoplasmacytic malignancies: determining demographic differences in the USARonald S Go, Herbert C Heien, Lindsey R Sangaralingham, et al.
The American Journal of Managed Care|August 30, 2021
Site of care potentially limits cost savings from biosimilarsJessica Chang, Pinar Karaca-Mandic, Ronald S Go, et al.
Pageof 41